Arcus Biosciences, Inc. RCUS 深 沪
已收盘 02-13 16:00:00 美东时间
18.92
-1.040
-5.21%
华盛通- 最 高20.53
- 今 开20.17
- 成交量 144.94万股
- 最 低 18.81
- 昨 收 19.96
- 总市值 23.02亿
- 52周最高 26.40
- 市盈率 静 --
- 换手率 1.19%
- 52周最低 6.50
- 委 比 31.27%
- 总股本 1.22亿
- 历史最高 49.10
- 量 比 1.64
- 振 幅 8.62%
- 历史最低 6.30
- 每 手 1
- 风险率 5.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | AppLovin评级分歧大！高盛等4家下调，韦德布什上调；HubSpot、休曼纳公司、Shopify、Unity、Paycom Software等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从39美元升至47美元；HC Wainwright & Co.：维持Agios制药"买入"评级，目标价从62美元升至65美元
02-13 15:30
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
02-12 22:21
Wells Fargo Downgrades Arcus Biosciences to Equal-Weight, Lowers Price Target to $23
Wells Fargo analyst Eva Fortea Verdejo downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to Equal-Weight and lowers the price target from $30 to $23.
02-12 21:42
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Morgan Stanley Downgrades Arcus Biosciences to Equal-Weight, Lowers Price Target to $20
Morgan Stanley analyst Terence Flynn downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to Equal-Weight and lowers the price target from $23 to $20.
01-08 20:11
TIGIT的转机还会出现吗？
文 | 氨基观察 被寄予“下一个免疫检查点”厚望的TIGIT，几乎走到了临床验证的尽头。 12月12日，Arcus Biosciences宣布其与吉利德合作研...
2025-12-19 10:36
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.
2025-12-13 02:35
Arcus Biosciences Discontinues Phase 3 STAR-221 Study With Gilead Following IDMC Futility Recommendation
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for casdatifan, a
2025-12-12 21:33
